Furthermore, genetic knockdown of Coch gene expression and pharmacological blockade of SFRP-1 impeded the progression of nonpathologic myopia by augmenting choroidal blood perfusion in the FDM model, implicating the potential of these 2 molecules as myopia intervention targets. The gene discussed is COCH; the disease is myopia.